Estrella Immunopharma, Inc.
ESLAW
Last
$0.05
Day
-12.5%
1y
+31.5%
5y
-72.3%
52w
-78.1%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
—
EMA 21
0.08
EMA 50
0.09
EMA 200
0.09
20d high
-61.4%
5y high
-78.1%
5y range
12th
Positions held
Your positionsESLAW isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-38
Hold
avoid
Signal
Strong Sell
Target
$0.08
Stop
$0.03
Stop distance
43.0%
Target vs last
+52.1%
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | -0.02 | Beta | -0.09 | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | — | ROA | -1.7% | Debt / equity | — |
| Current ratio | 0.28 | Free cash flow | $2.81M | Analyst recommendation | none | Mean target | — |
| 52w high | $0.05 | 52w low | $0.05 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$2.3M | -$2.3M | -$0.6M | -$4.8M | -$5.5M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$2.1M | -$2.3M | -$0.6M | -$4.8M | -$5.5M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$13.1M | -$7.3M | -$11.1M | -$1.7M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$13.1M | -$7.3M | -$11.1M | -$1.7M |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
No headlines.
Price (daily)
Full chart · RSI · MACD · patternsESLAW · daily-13.2% over 11 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin